NCT00865839View on ClinicalTrials.gov

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

March 31, 2002

Study Completion Date

March 31, 2002

Conditions
Healthy
Interventions
DRUG

Metformin HCl 500 mg tablets, single dose

A: Experimental Subjects received Purepac formulated products under fasting conditions

DRUG

CLUCOPHAGE® XR 500 mg tablets, single dose

B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865839 - A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter